{"id":259,"date":"2010-07-26T09:55:37","date_gmt":"2010-07-26T13:55:37","guid":{"rendered":"http:\/\/sciencebusiness.technewslit.com\/?p=259"},"modified":"2010-07-26T09:55:37","modified_gmt":"2010-07-26T13:55:37","slug":"clinical-trial-shows-drug-impact-on-fragile-x-syndrome","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=259","title":{"rendered":"Clinical Trial Shows Drug Impact on Fragile X Syndrome"},"content":{"rendered":"<figure id=\"attachment_260\" aria-describedby=\"caption-attachment-260\" style=\"width: 298px\" class=\"wp-caption alignleft\"><a href=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/TelAvivPark_200x300.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-260\" title=\"TelAvivPark_200x300\" src=\"http:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/TelAvivPark_200x300.jpg\" alt=\"Children in a Tel Aviv park (A. Kotok)\" width=\"298\" height=\"200\" srcset=\"https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/TelAvivPark_200x300.jpg 298w, https:\/\/technewslit.com\/sciencebusiness\/wp-content\/uploads\/2010\/07\/TelAvivPark_200x300-150x100.jpg 150w\" sizes=\"auto, (max-width: 298px) 100vw, 298px\" \/><\/a><figcaption id=\"caption-attachment-260\" class=\"wp-caption-text\">(A. Kotok)<\/figcaption><\/figure>\n<p>A drug made by <a href=\"http:\/\/www.seasidetherapeutics.com\/\">Seaside Therapeutics Inc.<\/a> of Cambridge, Massachusetts\u00a0 has shown results controlling symptoms of fragile X syndrome, an inherited disorder known to cause autism. The findings were reported\u00a0 this past weekend at a meeting of the National Fragile X Foundation.<\/p>\n<p>The results of the randomized, double-blind, placebo-controlled Phase 2 clinical trial showed subjects who were administered the Seaside Therapeutics drug STX209 score higher on most neuro-behavioral measures than than the placebo subjects. The subjects included pediatric patients with severe impairments of sociability.<\/p>\n<p>The company&#8217;s announcement quotes Randi Hagerman M.D., one of the investigators, who said, &#8220;Physicians and parents are reporting increased sociability and communication and decreased outbursts and tantrums.&#8221; Hagerman adds in some cases, patients have been withdrawn from other medications, including mood stabilizers, anti-depressants and anti-psychotics.<\/p>\n<p>The National Fragile X Foundation says <a href=\"http:\/\/www.fragilex.org\/html\/what.htm\">fragile X syndrome<\/a> is the most common cause of inherited mental impairment, which can range from learning disabilities to more severe cognitive or intellectual disabilities. Fragile X Syndrome is the most common known cause of autism or &#8220;autistic-like&#8221; behaviors that result in symptoms such as delays in speech and language development.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A drug made by Seaside Therapeutics Inc. of Cambridge, Massachusetts\u00a0 has shown results controlling symptoms of fragile X syndrome, an inherited disorder known to cause autism. The findings were reported\u00a0 this past weekend at a meeting of the National Fragile X Foundation. The results of the randomized, double-blind, placebo-controlled Phase 2 clinical trial showed subjects [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[28,27],"class_list":["post-259","post","type-post","status-publish","format-standard","hentry","category-products","tag-clinical-trials","tag-pharmaceuticals"],"_links":{"self":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=259"}],"version-history":[{"count":3,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/259\/revisions"}],"predecessor-version":[{"id":263,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=\/wp\/v2\/posts\/259\/revisions\/263"}],"wp:attachment":[{"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=259"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=259"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/technewslit.com\/sciencebusiness\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}